Literature DB >> 22490332

Comprehensive analysis of unique cases with extraordinary control over HIV replication.

Daniel Mendoza1, Sarah A Johnson, Bennett A Peterson, Ven Natarajan, Maria Salgado, Robin L Dewar, Peter D Burbelo, Nicole A Doria-Rose, Erin H Graf, Jamieson H Greenwald, Jessica N Hodge, William L Thompson, Nancy A Cogliano, Cheryl L Chairez, Catherine A Rehm, Sara Jones, Claire W Hallahan, Joseph A Kovacs, Irini Sereti, Omar Sued, Sheila A Peel, Robert J O'Connell, Una O'Doherty, Tae-Wook Chun, Mark Connors, Stephen A Migueles.   

Abstract

True long-term nonprogressors (LTNPs)/elite controllers (ECs) maintain durable control over HIV replication without antiretroviral therapy. Herein we describe 4 unique persons who were distinct from conventional LTNPs/ECs in that they had extraordinarily low HIV burdens and comparatively weak immune responses. As a group, typical LTNPs/ECs have unequivocally reactive HIV-1 Western blots, viral loads below the lower threshold of clinical assays, low levels of persistent viral reservoirs, an over-representation of protective HLA alleles, and robust HIV-specific CD8(+) T-cell responses. The 4 unique cases were distinguished from typical LTNPs/ECs based on weakly reactive Western blots, undetectable plasma viremia by a single copy assay, extremely low to undetectable HIV DNA levels, and difficult to isolate replication-competent virus. All 4 had at least one protective HLA allele and CD8(+) T-cell responses that were disproportionately high for the low antigen levels but comparatively lower than those of typical LTNPs/ECs. These unique persons exhibit extraordinary suppression over HIV replication, therefore, higher-level control than has been demonstrated in previous studies of LTNPs/ECs. Additional insight into the full spectrum of immune-mediated suppression over HIV replication may enhance our understanding of the associated mechanisms, which should inform the design of efficacious HIV vaccines and immunotherapies.

Entities:  

Mesh:

Year:  2012        PMID: 22490332      PMCID: PMC3367872          DOI: 10.1182/blood-2011-10-381996

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  52 in total

1.  Persistent low-level viremia in HIV-1 elite controllers and relationship to immunologic parameters.

Authors:  Florencia Pereyra; Sarah Palmer; Toshiyuki Miura; Brian L Block; Ann Wiegand; Alissa C Rothchild; Brett Baker; Rachel Rosenberg; Emily Cutrell; Michael S Seaman; John M Coffin; Bruce D Walker
Journal:  J Infect Dis       Date:  2009-09-15       Impact factor: 5.226

2.  Neutralizing antibodies do not mediate suppression of human immunodeficiency virus type 1 in elite suppressors or selection of plasma virus variants in patients on highly active antiretroviral therapy.

Authors:  Justin R Bailey; Kara G Lassen; Hung-Chih Yang; Thomas C Quinn; Stuart C Ray; Joel N Blankson; Robert F Siliciano
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

3.  Identification of a new recipient in the Sydney Blood Bank Cohort: a long-term HIV type 1-infected seroindeterminate individual.

Authors:  D Rhodes; A Solomon; W Bolton; J Wood; J Sullivan; J Learmont; N Deacon
Journal:  AIDS Res Hum Retroviruses       Date:  1999-11-01       Impact factor: 2.205

4.  Infrequent recovery of HIV from but robust exogenous infection of activated CD4(+) T cells in HIV elite controllers.

Authors:  B Julg; F Pereyra; M J Buzón; A Piechocka-Trocha; M J Clark; B M Baker; J Lian; T Miura; J Martinez-Picado; M M Addo; B D Walker
Journal:  Clin Infect Dis       Date:  2010-07-15       Impact factor: 9.079

5.  Clinical outcomes of elite controllers, viremic controllers, and long-term nonprogressors in the US Department of Defense HIV natural history study.

Authors:  Jason F Okulicz; Vincent C Marconi; Michael L Landrum; Scott Wegner; Amy Weintrob; Anuradha Ganesan; Braden Hale; Nancy Crum-Cianflone; Judith Delmar; Vincent Barthel; Gerald Quinnan; Brian K Agan; Matthew J Dolan
Journal:  J Infect Dis       Date:  2009-12-01       Impact factor: 5.226

6.  HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells.

Authors:  Michael R Betts; Martha C Nason; Sadie M West; Stephen C De Rosa; Stephen A Migueles; Jonathan Abraham; Michael M Lederman; Jose M Benito; Paul A Goepfert; Mark Connors; Mario Roederer; Richard A Koup
Journal:  Blood       Date:  2006-02-07       Impact factor: 22.113

7.  Spontaneous control of viral replication during primary HIV infection: when is "HIV controller" status established?

Authors:  Cécile Goujard; Marie-Laure Chaix; Olivier Lambotte; Christiane Deveau; Martine Sinet; Julien Guergnon; Valérie Courgnaud; Christine Rouzioux; Jean-François Delfraissy; Alain Venet; Laurence Meyer
Journal:  Clin Infect Dis       Date:  2009-09-15       Impact factor: 9.079

8.  Defective human immunodeficiency virus-specific CD8+ T-cell polyfunctionality, proliferation, and cytotoxicity are not restored by antiretroviral therapy.

Authors:  Stephen A Migueles; Kristin A Weeks; Eric Nou; Amy M Berkley; Julia E Rood; Christine M Osborne; Claire W Hallahan; Nancy A Cogliano-Shutta; Julia A Metcalf; Mary McLaughlin; Richard Kwan; JoAnn M Mican; Richard T Davey; Mark Connors
Journal:  J Virol       Date:  2009-09-02       Impact factor: 5.103

9.  Maintenance of viral suppression in HIV-1-infected HLA-B*57+ elite suppressors despite CTL escape mutations.

Authors:  Justin R Bailey; Thomas M Williams; Robert F Siliciano; Joel N Blankson
Journal:  J Exp Med       Date:  2006-05-08       Impact factor: 14.307

10.  Cycling of gut mucosal CD4+ T cells decreases after prolonged anti-retroviral therapy and is associated with plasma LPS levels.

Authors:  E J Ciccone; S W Read; P J Mannon; M D Yao; J N Hodge; R Dewar; C L Chairez; M A Proschan; J A Kovacs; I Sereti
Journal:  Mucosal Immunol       Date:  2009-12-02       Impact factor: 7.313

View more
  49 in total

1.  Defective HIV-1 proviruses produce novel protein-coding RNA species in HIV-infected patients on combination antiretroviral therapy.

Authors:  Hiromi Imamichi; Robin L Dewar; Joseph W Adelsberger; Catherine A Rehm; Una O'Doherty; Ellen E Paxinos; Anthony S Fauci; H Clifford Lane
Journal:  Proc Natl Acad Sci U S A       Date:  2016-07-18       Impact factor: 11.205

Review 2.  Unravelling the mechanisms of durable control of HIV-1.

Authors:  Bruce D Walker; Xu G Yu
Journal:  Nat Rev Immunol       Date:  2013-07       Impact factor: 53.106

3.  HIV antibody characterization as a method to quantify reservoir size during curative interventions.

Authors:  Peter D Burbelo; Ahmad Bayat; Craig S Rhodes; Rebecca Hoh; Jeffrey N Martin; Rémi Fromentin; Nicolas Chomont; Gero Hütter; Joseph A Kovacs; Steven G Deeks
Journal:  J Infect Dis       Date:  2013-11-28       Impact factor: 5.226

4.  Monitoring Integration over Time Supports a Role for Cytotoxic T Lymphocytes and Ongoing Replication as Determinants of Reservoir Size.

Authors:  Marilia Rita Pinzone; Erin Graf; Lindsay Lynch; Brigit McLaughlin; Frederick M Hecht; Mark Connors; Stephen A Migueles; Wei-Ting Hwang; Giuseppe Nunnari; Una O'Doherty
Journal:  J Virol       Date:  2016-11-14       Impact factor: 5.103

5.  Anti-Human Immunodeficiency Virus Antibodies in the Cerebrospinal Fluid: Evidence of Early Treatment Impact on Central Nervous System Reservoir?

Authors:  Peter D Burbelo; Richard W Price; Lars Hagberg; Hiroyu Hatano; Serena Spudich; Steven G Deeks; Magnus Gisslén
Journal:  J Infect Dis       Date:  2018-03-13       Impact factor: 5.226

6.  The potential complexity and need for caution when interpreting atypical human immunodeficiency virus reactivity in blood donors.

Authors:  Philip Kiely; Mike Catton; Dianne Brown; Doris Chibo; Theo Karapanagiotidis; Denis Spelman
Journal:  Blood Transfus       Date:  2015-07-16       Impact factor: 3.443

Review 7.  HIV Persistence in Gut-Associated Lymphoid Tissues: Pharmacological Challenges and Opportunities.

Authors:  Corbin G Thompson; Cynthia L Gay; Angela D M Kashuba
Journal:  AIDS Res Hum Retroviruses       Date:  2017-05-16       Impact factor: 2.205

8.  Immune Control of HIV.

Authors:  Muthukumar Balasubramaniam; Jui Pandhare; Chandravanu Dash
Journal:  J Life Sci (Westlake Village)       Date:  2019-06

Review 9.  HIV and HLA class I: an evolving relationship.

Authors:  Philip J R Goulder; Bruce D Walker
Journal:  Immunity       Date:  2012-09-21       Impact factor: 31.745

10.  Large granular lymphocytes are universally increased in human, macaque, and feline lentiviral infection.

Authors:  Wendy S Sprague; Cristian Apetrei; Anne C Avery; Robert L Peskind; Sue Vandewoude
Journal:  Vet Immunol Immunopathol       Date:  2015-07-29       Impact factor: 2.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.